Fast indirect fluorine-18 labeling of protein/peptide using the useful 6-fluoronicotinic acid-2,3,5,6-tetrafluorophenyl prosthetic group: A method comparable to direct fluorination.

Falguni Basuli, Xiang Zhang, Carolyn C Woodroofe, Elaine M Jagoda, Peter L Choyke, Rolf E Swenson
Author Information
  1. Falguni Basuli: Imaging Probe Development Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Rockville, MD, USA.
  2. Xiang Zhang: Imaging Probe Development Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Rockville, MD, USA.
  3. Carolyn C Woodroofe: Imaging Probe Development Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Rockville, MD, USA.
  4. Elaine M Jagoda: Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  5. Peter L Choyke: Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  6. Rolf E Swenson: Imaging Probe Development Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Rockville, MD, USA.

Abstract

Fluorine-18 labeling of biomolecules is mostly performed by an indirect labeling method using a prosthetic group. Fluorine-18 labeled 6-fluoronicotinic acid-2,3,5,6-tetrafluorophenyl ester is a useful prosthetic group to radiolabel a protein. Recently, we reported an improved preparation of this prosthetic group. To test the conjugation efficiency of the labeled ester prepared by this method, we have performed conjugation reactions with a peptide, a protein, and a small molecule. Prostate-specific membrane antigen targeting small molecule [ F]DCFPyL, αvβ3 integrin receptors targeting peptide [ F]c(RGDfK) and [ F]albumin were prepared in good radiochemical yields. The conjugation reactions were completed at 40°C to 50°C in 10 minutes. The overall radiochemical yield was 25% to 43% in 30 to 45 minutes.

Keywords

References

Nat Rev Urol. 2016 Apr;13(4):226-35 [PMID: 26902337]
Ther Deliv. 2013 Nov;4(11):1443-67 [PMID: 24228993]
Clin Cancer Res. 2011 Dec 15;17 (24):7645-53 [PMID: 22042970]
Bioconjug Chem. 2008 Sep;19(9):1871-9 [PMID: 18754574]
Biomaterials. 2013 Aug;34(26):6249-60 [PMID: 23702147]
Mol Imaging Biol. 2015 Aug;17 (4):565-74 [PMID: 25896814]
Mol Imaging Biol. 2015 Aug;17 (4):575-84 [PMID: 26013479]
Phys Med Biol. 1999 Mar;44(3):781-99 [PMID: 10211810]
J Nucl Med. 2016 Oct;57(Suppl 3):43S-48S [PMID: 27694171]
Chem Commun (Camb). 2015 Sep 11;51(70):13542-5 [PMID: 26221637]
Curr Top Med Chem. 2010;10(16):1669-79 [PMID: 20583991]
J Nucl Med. 2009 Jan;50(1):116-22 [PMID: 19091899]
Integr Biol (Camb). 2010 Aug;2(7-8):326-37 [PMID: 20657951]
J Nucl Med. 2004 May;45(5):892-902 [PMID: 15136641]
Drug Discov Today. 2015 Jan;20(1):122-8 [PMID: 25450771]
J Nucl Med. 2008 May;49(5):804-13 [PMID: 18413392]
J Nucl Med. 2008 Mar;49(3):453-61 [PMID: 18287274]
Bioconjug Chem. 2004 Jan-Feb;15(1):61-9 [PMID: 14733584]
Nat Rev Urol. 2009 Jun;6(6):317-23 [PMID: 19434102]
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [PMID: 19474385]
Appl Radiat Isot. 2003 Jul;59(1):43-8 [PMID: 12878121]
PLoS Med. 2005 Mar;2(3):e70 [PMID: 15783258]
Theranostics. 2012;2(6):607-17 [PMID: 22768028]
Nucl Med Biol. 2013 Jul;40(5):710-6 [PMID: 23706550]
Appl Radiat Isot. 2011 Feb;69(2):410-4 [PMID: 20965741]
Nat Protoc. 2006;1(4):1655-61 [PMID: 17487148]
Bioconjug Chem. 2009 Dec;20(12):2254-61 [PMID: 19921791]
Mol Imaging Biol. 2010 Oct;12 (5):530-8 [PMID: 19949981]
Chem Biol Drug Des. 2013 Jan;81(1):136-47 [PMID: 23253135]
Nucl Med Biol. 2007 Jan;34(1):5-15 [PMID: 17210457]
Eur J Nucl Med Mol Imaging. 2015 Nov;42(12 ):1850-8 [PMID: 26062933]
Angew Chem Int Ed Engl. 2014 Oct 20;53(43):11416-8 [PMID: 25243361]
Theranostics. 2016 Jan 01;6(1):78-92 [PMID: 26722375]
Bioconjug Chem. 2009 Feb;20(2):317-21 [PMID: 19132825]
J Nucl Med. 2008 Jun;49(6):879-86 [PMID: 18483090]
Angew Chem Int Ed Engl. 2008;47(26):4922-5 [PMID: 18496798]
Nucl Med Biol. 2015 Mar;42(3):219-25 [PMID: 25533724]
Angew Chem Int Ed Engl. 2014 Oct 27;53(44):11876-80 [PMID: 25196467]
Theranostics. 2011;1:30-47 [PMID: 21544229]
Nucl Med Biol. 2016 Dec;43(12 ):770-772 [PMID: 27693671]
Adv Drug Deliv Rev. 2010 Aug 30;62(11):1031-51 [PMID: 20854860]
Chem Rev. 2008 May;108(5):1501-16 [PMID: 18426240]
J Med Chem. 2010 Feb 25;53(4):1732-40 [PMID: 20088512]
Cancer Res. 2002 Sep 15;62(18):5139-43 [PMID: 12234975]
Bioconjug Chem. 2012 Jan 18;23(1):106-14 [PMID: 22148255]
Acc Chem Res. 2016 Jul 19;49(7):1333-43 [PMID: 27054808]
Chem Rev. 2016 Jan 27;116(2):719-66 [PMID: 26751274]
Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S11-30 [PMID: 22388624]
Nat Rev Drug Discov. 2008 Jul;7(7):591-607 [PMID: 18591980]
Bioconjug Chem. 2007 May-Jun;18(3):989-93 [PMID: 17429938]
Bioconjug Chem. 2008 Aug;19(8):1684-8 [PMID: 18627198]
J Labelled Comp Radiopharm. 2014 Apr;57(4):219-23 [PMID: 24408125]
Bioconjug Chem. 2007 Nov-Dec;18(6):1987-94 [PMID: 18030991]
Angew Chem Int Ed Engl. 2015 Mar 9;54(11):3216-21 [PMID: 25653137]
Bioconjug Chem. 2008 Apr;19(4):951-7 [PMID: 18341272]
Mol Pharm. 2011 Oct 3;8(5):1775-82 [PMID: 21800885]
Bioconjug Chem. 2015 Jan 21;26(1):1-18 [PMID: 25473848]
Molecules. 2014 Dec 08;19(12):20536-20556 [PMID: 25493636]
Bioconjug Chem. 2016 Mar 16;27(3):790-8 [PMID: 26837664]
J Labelled Comp Radiopharm. 2016 Sep;59(11):439-50 [PMID: 27470935]
EJNMMI Res. 2016 Dec;6(1):40 [PMID: 27142881]

Grants

  1. HHSN261200800001C/CCR NIH HHS
  2. HHSN261200800001E/NCI NIH HHS
  3. Z99 HL999999/Intramural NIH HHS

MeSH Term

Albumins
Amino Acid Sequence
Antigens, Surface
Fluorine Radioisotopes
Glutamate Carboxypeptidase II
Halogenation
Isotope Labeling
Kinetics
Oligopeptides

Chemicals

Albumins
Antigens, Surface
Fluorine Radioisotopes
Oligopeptides
arginyl-glycyl-aspartic acid
FOLH1 protein, human
Glutamate Carboxypeptidase II
Fluorine-18

Word Cloud

Similar Articles

Cited By